Cargando…

Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS

Detalles Bibliográficos
Autores principales:	Hari, BN Vedha, Dhevendaran, K, Narayanan, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3344724/ http://dx.doi.org/10.1186/1471-2334-12-S1-P7

Ejemplares similares

Immunological response after initiation of second line anti-retroviral therapy in HIV patients
por: Achappa, Basavaprabhu, et al.
Publicado: (2012)

Efavirenz use and contraceptive methods in HIV-positive women in a large urban cohort
por: Seaton, RA, et al.
Publicado: (2010)

The evolution of HIV-1 subtypes and disease progression among adults on anti-retroviral drugs in Northern Tanzania
por: Shao, E, et al.
Publicado: (2012)

CD4 count and viral load response to different anti retroviral treatment regimen among AIDS patients from Mumbai, Western India
por: Shankarkumar, Umapathy, et al.
Publicado: (2009)

Effect of anti retroviral therapy on mucocutaneous manifestations among HIV infected patients in a tertiary care centre in India
por: Prabhakaran, N, et al.
Publicado: (2014)

Survival and prognosis of HIV-associated non-Hodgkin-lymophma in the era of combined anti-retroviral therapy, a European multi-cohort study
por: Bohlius, J
Publicado: (2009)

The management of acute retroviral syndrome
por: Hristea, A, et al.
Publicado: (2010)

Efavirenz’ adverse reactions: a possible link between depression and gynecomastia
por: Diaconu, Ioan Alexandru, et al.
Publicado: (2014)

Ubiquitination-dependent, proteasomal degradation of the retroviral oncoprotein Tax by niclosamide, an anti-helminthic molecule
por: Xiang, Di, et al.
Publicado: (2014)

The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
por: Maganda, Betty A, et al.
Publicado: (2015)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Investigating retroviral envelope proteome plasticity
por: Heider, Susanne, et al.
Publicado: (2013)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

The dose adherence computation model: a critical review of anti-retroviral drug level of adherence computation
por: Ofosu, D, et al.
Publicado: (2009)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Development of a single-tube, low-cost, analytical process to extract, separate and determine efavirenz and rifampicin plasma concentrations in HIV/TB co-infected patients
por: Fox, D, et al.
Publicado: (2010)

Street hawking and HIV/AIDS
por: James, Ameh, et al.
Publicado: (2006)

Homeless people and HIV/AIDS
por: Dewi, Sarah
Publicado: (2006)

HIV/AIDS epidemic in Belarus
por: Eremin, Vladimir, et al.
Publicado: (2010)

Activation of antigen-presenting cells by endogenous retroviral RNA
por: Moyes, D, et al.
Publicado: (2005)

Characterisation of FEZ1-mediated inhibition of retroviral replication
por: Brown, Craig, et al.
Publicado: (2009)

SAMHD1-dependent retroviral control and escape in mice
por: Rehwinkel, Jan, et al.
Publicado: (2013)

Applications of RNA structure analysis to retroviral packaging and anti-retroviral therapeutic discovery
por: Weeks, Kevin M, et al.
Publicado: (2011)

Our experience in second line Anti Retroviral Therapy (ART) At State Aids Clinical Expert Panel (SACEP) Clinic, Centre of Excellence (CoE), Art Centre, B. J. Medical College, Civil Hospital, Ahmedabad
por: Mankad, Bankim, et al.
Publicado: (2010)

Investigation of retroviral integration preference via high-throughput sequencing
por: LaFave, Matthew C, et al.
Publicado: (2012)

In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV
por: K, Priya Dharshini, et al.
Publicado: (2022)

Long highways and risk of HIV/AIDS
por: Bhalla, S, et al.
Publicado: (2006)

Tuberculosis in HIV/AIDS patients in Arad
por: Prişcă, Mirandolina, et al.
Publicado: (2013)

Lamivudine‐conjugated and efavirenz‐loaded G2 dendrimers: Novel anti‐retroviral nano drug delivery systems
por: Pargoo, Esmaeel Mohammadi, et al.
Publicado: (2021)

P03-05. CD4 targeted vaccination in retroviral infection
por: Pike, R, et al.
Publicado: (2009)

Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral treatment amongst an adult treatment cohort from South Africa
por: Bock, P, et al.
Publicado: (2010)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

The Guinean traditional medicine in the treatment of HIV/AIDS
por: Baldé, AM, et al.
Publicado: (2006)

Generalized tuberculosis in HIV-infected patients with AIDS
por: Zimina, VN, et al.
Publicado: (2010)

HIV-AIDS epidemiological model in Constanța County
por: Șerban, Iulia Gabriela, et al.
Publicado: (2014)

Heart rate variability in HIV-infected and AIDS
por: Galdino, Gabriela AM, et al.
Publicado: (2015)

1048. Weight Gain after Initiation of Anti-Retroviral Therapy in Acute HIV-1
por: Kaur, Harmanpreet, et al.
Publicado: (2020)

Preclinical test of a lentivirus-mediated RNAi gene therapy against HIV-AIDS in the humanized mouse model
por: Centlivre, Mireille, et al.
Publicado: (2011)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

The prevalence of HIV-1 DNA in AIDS-related lymphoma and Kaposi Sarcoma throughout the AIDS epidemic
por: Huysentruyt, Leanne C, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bh51o57ufjh797a6ljile6p7sq